IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
Imunon, Inc. (IMNN)
Company Research
Source: GlobeNewswire
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivotal trial of DNA-mediated IL-12 therapeutic Company to hold conference call on Tuesday, March 25, 2025, at 2:00 p.m. ET LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) is aligned with the protocol for the Phase 3 pivotal trial, called OVATION 3, of its lead candidate IMNN-001 in development for the treatment of women with newly diagnosed advanced ovar
Read more
Impact Snapshot
Event Time:
IMNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNN alerts
High impacting Imunon, Inc. news events
Weekly update
A roundup of the hottest topics
IMNN
News
- IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual MeetingGlobeNewswire
- Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- Imunon, Inc. (NASDAQ: IMNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $29.00 price target on the stock.MarketBeat
- IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer [Yahoo! Finance]Yahoo! Finance
IMNN
Analyst Actions
- 3/26/25 - HC Wainwright
IMNN
Sec Filings
- 4/4/25 - Form S-1
- 3/24/25 - Form 8-K
- 3/18/25 - Form 4
- IMNN's page on the SEC website